The strong EPS beat and cash runway are positives, but the stock has historically been volatile post-earnings. Monitor the mid-2026 opt-in decision on the Gilead collaboration as a key catalyst.
Price Chart
Executive Summary
Assembly Biosciences reported Q1 2026 EPS of -$0.54, beating consensus of -$0.73 by 26%, while collaboration revenue from Gilead fell 12.8% YoY to $8.2M. Cash of $226.6M funds operations into 2028; key near-term catalyst is the mid-2026 opt-in decision on the herpesvirus program.
Key Financial Metrics
Key Facts
- EPS -$0.54 beat consensus of -$0.73 by 26%
- Collaboration revenue from Gilead $8.2M, down from $9.4M YoY
- Cash and marketable securities $226.6M, projected to fund operations into 2028
- Company to evaluate opt-in to 40% U.S. cost-profit share on herpesvirus program by mid-2026
- Phase 2 study for ABI-6250 in HDV expected to initiate in Q4 2026
Financial Impact
EPS beat of $0.19 vs consensus; revenue decline of $1.2M YoY
Risk Factors
- Dependence on Gilead collaboration for revenue and approval
- No approved products; clinical failures could halt pipeline
- Revenue declining YoY may signal reduced collaboration activity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290491 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 15, 2026 10w ago | Institutional Cluster | $30.01 $35.28 | ▲ +17.56% | ▲ +18.75% | $20.30 (−32.36%) |
Aug 13, 2026 10w ago | Press Release | $32.95 $34.38 | ▲ +4.34% | ▲ +5.71% | $20.30 (−38.39%) |
Jun 11, 2026 19w ago | Institutional Cluster | $22.53 $24.15 | ▲ +7.19% | ▲ +6.76% | $20.30 (−9.90%) |
Jun 5, 2026 20w ago | 8-K | $22.56 $23.34 | ▲ +3.48% | ▲ +1.37% | $20.30 (−10.00%) |
May 22, 2026 22w ago | 424B5 | $28.75 $26.92 | ▲ +6.37% | ▲ +7.45% | $20.30 (+29.39%) |
May 22, 2026 22w ago | 8-K | $28.34 $26.92 | ▼ −5.01% | ▼ −6.67% | $20.30 (−28.37%) |
May 22, 2026 22w ago | Press Release | $28.34 $26.92 | ▼ −5.01% | ▼ −6.67% | $20.30 (−28.37%) |
May 7, 2026 24w ago | Press Release | $29.74 $30.30 | ▲ +1.88% | ▲ +0.42% | $20.30 (−31.74%) |
Mar 30, 2026 30w ago | EFFECT | $26.64 $28.53 | ▲ +7.09% | ▲ +2.79% | $20.30 (−23.80%) |
Mar 19, 2026 31w ago | Press Release | $28.46 $27.70 | ▼ −2.67% | ▼ −0.52% | $20.30 (−28.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers